NCT05820932 (ABC) is a clinical trial of Blood-based assay in Prostate Cancer, sponsored by University of California, San Francisco.

Who is sponsoring NCT05820932?

NCT05820932 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT05820932?

Interventions in NCT05820932: Blood-based assay, Cognitive assessments, Quality of Life Surveys.

What condition does NCT05820932 study?

NCT05820932 studies Prostate Cancer.

Is NCT05820932 still recruiting?

NCT05820932 is currently active, enrolled. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT05820932: ABC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Cognitive Decline From Androgen Deprivation Therapy

Active, enrolled Last updated 24 February 2026

What this trial tests

trial testing Blood-based assay in Prostate Cancer in 32 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 May 2023

Primary endpoint
28 February 2026

28 February 2026

Quick facts

Lead sponsor	University of California, San Francisco
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	32
Start date	22 May 2023
Primary completion	28 February 2026
Estimated completion	28 February 2026
Sites	1 location across United States

Drugs / interventions tested

Blood-based assay
Cognitive assessments
Quality of Life Surveys

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of California, San Francisco

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Androgen Deprivation Therapy (ADT) is associated with cognitive impairment and dementia in men with prostate cancer. Pre-clinical data suggest that ADT-induced hypogonadism leads to accumulation of beta-amyloid plaques in the hippocampus, a pathological hallmark of Alzheimer's Disease (AD). Neuroimaging Functional magnetic resonance imaging (fMRI) studies also demonstrate that ADT decreases metabolic activity in the parietal, occipital, and prefrontal cortices. Multiple prospective cohort and population-based clinical studies have been conducted to test the association between ADT and cognitive impairment and/or dementia. Plasma biomarkers have been developed to predict brain amyloidosis, a key pathological feature of AD and a risk factor for developing dementia due to AD. The advantage of a blood-based assay is the lower cost, invasiveness, and time compared to cerebrospinal fluid (CSF) and Positron Emission Tomography (PET)-based biomarkers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations.
Neth BJ, Wefel JS, Nead KT. · · 2025 · PMID 40376525 · DOI 10.21037/tau-2024-747

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05820932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing